PARP inhibitor maintenance for primary ovarian cancer - A missed opportunity for precision medicine

被引：5

作者：

Wethington, Stephanie L. ^{[1
]}

Wahner-Hendrickson, Andrea E. ^{[2
]}

Swisher, Elizabeth M. ^{[3
]}

Kaufmann, Scott H. ^{[2
]}

Karlan, Beth Y. ^{[4
]}

Fader, Amanda Nickles ^{[1
]}

Dowdy, Sean C. ^{[5
]}

机构：

[1] Johns Hopkins Univ Hosp, Kelly Gynecol Oncol Serv, Dept Gynecol & Obstet, Baltimore, MD 21287 USA

[2] Mayo Clin, Dept Oncol, Rochester, MN USA

[3] Univ Washington, Div Gynecol Oncol, Seattle, WA 98195 USA

[4] Cedars Sinai Med Ctr, Womens Canc Program, Los Angeles, CA 90048 USA

[5] Mayo Clin, Div Gynecol Oncol, Rochester, MN 55901 USA

来源：

GYNECOLOGIC ONCOLOGY | 2021年 / 163卷 / 01期

关键词：

D O I：

10.1016/j.ygyno.2021.08.002

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：11 / 13

页数：3

共 11 条

[1] Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer [J].

Coleman, R. L. ;

Fleming, G. F. ;

Brady, M. F. ;

Swisher, E. M. ;

Steffensen, K. D. ;

Friedlander, M. ;

Okamoto, A. ;

Moore, K. N. ;

Ben-Baruch, N. Efrat ;

Werner, T. L. ;

Cloven, N. G. ;

Oaknin, A. ;

DiSilvestro, P. A. ;

Morgan, M. A. ;

Nam, J. -H. ;

Leath, C. A., III ;

Nicum, S. ;

Hagemann, A. R. ;

Littell, R. D. ;

Cella, D. ;

Baron-Hay, S. ;

Garcia-Donas, J. ;

Mizuno, M. ;

Bell-McGuinn, K. ;

Sullivan, D. M. ;

Bach, B. A. ;

Bhattacharya, S. ;

Ratajczak, C. K. ;

Ansell, P. J. ;

Dinh, M. H. ;

Aghajanian, C. ;

Bookman, M. A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (25) :2403-2415

[2] Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer [J].

Gonzalez-Martin, A. ;

Pothuri, B. ;

Vergote, I. ;

DePont Christensen, R. ;

Graybill, W. ;

Mirza, M. R. ;

McCormick, C. ;

Lorusso, D. ;

Hoskins, P. ;

Freyer, G. ;

Baumann, K. ;

Jardon, K. ;

Redondo, A. ;

Moore, R. G. ;

Vulsteke, C. ;

O'Cearbhaill, R. E. ;

Lund, B. ;

Backes, F. ;

Barretina-Ginesta, P. ;

Haggerty, A. F. ;

Rubio-Perez, M. J. ;

Shahin, M. S. ;

Mangili, G. ;

Bradley, W. H. ;

Bruchim, I. ;

Sun, K. ;

Malinowska, I. A. ;

Li, Y. ;

Gupta, D. ;

Monk, B. J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (25) :2391-2402

[3] Patient cost sharing during poly(adenosine diphosphate-ribose) polymerase inhibitor treatment in ovarian cancer [J].

Harrison, Ross F. ;

Fu, Shuangshuang ;

Sun, Charlotte C. ;

Zhao, Hui ;

Lu, Karen H. ;

Giordano, Sharon H. ;

Meyer, Larissa A. .

AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2021, 225 (01) :68.e1-68.e11

[4] Total and out-of-pocket costs for PARP inhibitors among insured ovarian cancer patients [J].

Liang, Margaret I. ;

Chen, Ling ;

Hershman, Dawn L. ;

Hillyer, Grace C. ;

Huh, Warner K. ;

Guyton, Allison ;

Wright, Jason D. .

GYNECOLOGIC ONCOLOGY, 2021, 160 (03) :793-799

[5] Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer [J].

Moore, K. ;

Colombo, N. ;

Scambia, G. ;

Kim, B. -G. ;

Oaknin, A. ;

Friedlander, M. ;

Lisyanskaya, A. ;

Floquet, A. ;

Leary, A. ;

Sonke, G. S. ;

Gourley, C. ;

Banerjee, S. ;

Oza, A. ;

Gonzalez-Martin, A. ;

Aghajanian, C. ;

Bradley, W. ;

Mathews, C. ;

Liu, J. ;

Lowe, E. S. ;

Bloomfield, R. ;

DiSilvestro, P. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (26) :2495-2505

[6] Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database [J].

Morice, Pierre-Marie ;

Leary, Alexandra ;

Dolladille, Charles ;

Chretien, Basile ;

Poulain, Laurent ;

Gonzalez-Martin, Antonio ;

Moore, Kathleen ;

O'Reilly, Eileen Mary ;

Ray-Coquard, Isabelle ;

Alexandre, Joachim .

LANCET HAEMATOLOGY, 2021, 8 (02) :e122-e134

[7] Cost-effectiveness of Maintenance Therapy Based on Molecular Classification Following Treatment of Primary Epithelial Ovarian Cancer in the United States [J].

Penn, Courtney A. ;

Wong, Melissa S. ;

Walsh, Christine S. .

JAMA NETWORK OPEN, 2020, 3 (12)

[8] State-of-the-art strategies for targeting the DNA damage response in cancer [J].

Pilie, Patrick G. ;

Tang, Chad ;

Mills, Gordon B. ;

Yap, Timothy A. .

NATURE REVIEWS CLINICAL ONCOLOGY, 2019, 16 (02) :81-104

[9]

Pothuri B.H.S., ANN ONCOL, V31

[10] Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer [J].

Ray-Coquard, I. ;

Pautier, P. ;

Pignata, S. ;

Perol, D. ;

Gonzalez-Martin, A. ;

Berger, R. ;

Fujiwara, K. ;

Vergote, I. ;

Colombo, N. ;

Maenpaa, J. ;

Selle, F. ;

Sehouli, J. ;

Lorusso, D. ;

Alia, E. M. Guerra ;

Reinthaller, A. ;

Nagao, S. ;

Lefeuvre-Plesse, C. ;

Canzler, U. ;

Scambia, G. ;

Lortholary, A. ;

Marme, F. ;

Combe, P. ;

de Gregorio, N. ;

Rodrigues, M. ;

Buderath, P. ;

Dubot, C. ;

Burges, A. ;

You, B. ;

Pujade-Lauraine, E. ;

Harter, P. .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (25) :2416-2428

← 1 2 →